YES, Robert — Lock In My 62%-Off Charter Rate to The Kiyosaki Letter, the Most Overlooked Research Advantage in America.
Plus reserve all 5 FREE bonus reports — including the full Conexeu Sciences (CNXU) briefing — the FAKE book (Annual only), and immediate access to my P.I.P. Portfolio with 42 paydays per year.
My Rich Dad taught me a long time ago that the most dangerous thing in America is not poverty. It's the slow-motion replacement of real assets with fake ones.
Fake money that loses value every year. Fake teachers selling theories they've never tested with their own capital. Fake assets dressed up as the real thing, until they collapse. I wrote a book about it called FAKE. And the longer I work in this business, the more convinced I become that the difference between the people who build real wealth and the people who don't comes down to a single skill: the ability to tell the difference.
That is exactly what I built The Kiyosaki Letter to do.
Every month, I sit down with my research team and we hunt for one big idea — one real opportunity — that the financial press has either missed entirely or gotten wrong. Sometimes it's an energy story (last month it was the way the Iran war is repricing every American pipeline operator). Sometimes it's a tax loophole most CPAs don't know exists. And right now, the idea on my desk is the most overlooked biotech in America — a small company called Conexeu Sciences (NASDAQ: CNXU) that, in my opinion, is sitting on the first true breakthrough injectable aesthetics has seen since Botox launched in 1989.
That CNXU report — along with everything else inside The Kiyosaki Letter — is yours the moment you enroll below. But the report is not why I want you to join. I want you to join because The Kiyosaki Letter is the kind of research advantage that compounds over time, every month, for as long as you are a member.
Let me show you what that means.
The Most Overlooked Research Advantage in America
One big idea per month. An 80% win rate. A growing library of Special Reports. And a real-asset portfolio paying 42 times a year.
Most financial newsletters fall into one of two traps. Either they fire off so many recommendations every week that you can't keep track of what to actually do — or they sell you a single “secret stock” pitch and then disappear once you've paid.
The Kiyosaki Letter is built on a different model. Every month, you get one carefully researched big idea — the kind of opportunity my Rich Dad would have called “real” — along with the analysis, the entry guidance, and the time-sensitive Flash Alerts if anything changes.
Here is what makes The Kiyosaki Letter different:
- ONE BIG IDEA PER MONTH. Not 40 picks a week. One. Researched in depth, presented in plain English, and tracked across the months that follow so you always know where you stand.
- AN 80% WIN RATE SINCE LAUNCH. The number speaks for itself. (Past performance does not guarantee future results.)
- THE P.I.P. PORTFOLIO. My Patriot Income Plan — 14 real-asset positions producing 42 income payouts per year. Pipelines, energy infrastructure, and the kind of hard-asset cash flow that does not depend on the next Fed meeting.
- THE SPECIAL REPORTS LIBRARY. Every research report I have ever published — a deep, growing archive of investment research across energy, real estate, biotech, and tax strategy. Yours to keep, forever.
- TIME-SENSITIVE FLASH ALERTS. When a position needs action — buy more, hold, trim, exit — you get a same-day notification. No checking your inbox three weeks late and missing the move.
- MONTHLY P.I.P. VIDEO UPDATES. Every month my team walks you through every position in the entire P.I.P. portfolio — what to buy more of, what to hold, what to sell, and what positions to potentially swap in.
- FREEDOM FINANCIAL NEWS + KIYOSAKI UNCENSORED. My weekly market commentary in plain English, plus my unfiltered take on the stories the financial press is afraid to touch.
Right now, the lead featured research inside The Kiyosaki Letter is my full briefing on Conexeu Sciences (NASDAQ: CNXU) — the small biotech I believe could become the first true category-defining innovation in injectable aesthetics in over twenty years. You'll get that report the moment you enroll, along with everything else listed below.
This Month's Featured Research: Conexeu Sciences (NASDAQ: CNXU)
The biotech Wall Street hasn't priced in yet — a real regenerative tissue platform built to do what synthetic fillers cannot.
The most-discussed trade in healthcare right now is the GLP-1 weight-loss drug boom. Eli Lilly's tirzepatide franchise alone did roughly $36.5 billion last year. Wall Street has priced that trade and rewarded the early movers handsomely.
But the trade that I believe matters more is what happens AFTER tens of millions of patients lose the weight — when they look in the mirror and see a hollowed-out, prematurely aged version of themselves staring back. The popular press calls it “Ozempic Face.” Boston
Consulting Group projects the provider revenue from this single problem could grow from $700 million to $2 billion in five years.And the legacy injectable aesthetics industry — an $11 billion market that hasn't seen a true technology breakthrough since 1989 — was not built to fix it.
The current solutions are hyaluronic acid fillers. Synthetic sugars. Or biostimulators — chemicals designed to trigger inflammation. They were not engineered to rebuild tissue. They were engineered to fill space. They are, in the truest sense of the word, FAKE.
Conexeu Sciences (NASDAQ: CNXU) is different. The company has spent over a decade at the University of British Columbia developing a regenerative tissue platform called CXU — a flowable, temperature-sensitive collagen scaffold that lets the body rebuild real tissue from the inside out. Not synthetic. Not inflammatory. Patented in 40+ countries. Backed by 11 peer-reviewed publications. And led by the team that ran Galderma's North American aesthetics business before they got here.
My full briefing on the company is one of the featured research reports you get the moment you enroll below.
The Two Featured CNXU Research Reports (Yours FREE With Your Enrollment)
The full Conexeu Sciences (NASDAQ: CNXU) briefing. Inside: my nine reasons for putting CNXU on every Kiyosaki Letter reader's due-diligence list, the Ten Minute Tissue technology breakdown, the team's track record (the operators who ran Galderma North America before Conexeu), the regulatory pathway, and the five high-margin verticals I see the company targeting.
How Allergan, Galderma, and Merz built generational franchises in injectable aesthetics — and what the historical pattern of multi-billion-dollar M&A in this sector could mean for the next category-defining platform. Read alongside the main CNXU briefing for the full picture.
Here's Everything You Get The Moment You Enroll
Over $1,000 in total membership value — yours today for as little as $49.
My flagship monthly research briefing — one big idea per month, with full analysis, entry guidance, and weekly market commentary in plain English. Since launch, an 80% win rate.
My Patriot Income Plan — 14 real-asset positions producing 42 income payouts per year. Pipeline operators, energy infrastructure, and hard-asset cash flow. All positions, all entry prices, all current prices, all forward dividends.
Every month, my team walks you through every position in the portfolio — what to buy more of, what to hold, what to sell, what to swap in.
Immediate access to every Special Report I have ever published — a deep, growing archive across energy, real estate, biotech, and tax strategy. Yours to keep, forever.
The full Conexeu Sciences (NASDAQ: CNXU) briefing — my nine reasons for putting CNXU on every reader's due-diligence list, the Ten Minute Tissue technology breakdown, the team's track record, the regulatory pathway, and the five verticals I see the company targeting.
How Allergan, Galderma, and Merz built generational franchises in injectable aesthetics — and what the historical pattern of multi-billion-dollar M&A in this sector could mean for the next category-defining platform.
America is building a second energy grid to power 3,000+ AI data centers — and one overlooked sector is quietly becoming its most critical fuel source. This report names the specific company positioned to profit from the greatest energy build-out in human history, and why it's already paying investors automatic income.
As Iran's conflict reshapes the global energy map, the nations and companies that control America's pipelines, LNG terminals, and natural gas infrastructure are gaining leverage the world hasn't seen in decades. This report details how the war has turbocharged demand for domestic energy — and which P.I.P. holdings stand to benefit most.
While U.S. acquisition of Greenland remains unlikely, new opportunities to secure rare earth metals, expand U.S. military presence, and establish stronger economic and shipping ties have emerged. I'll tell you which three anchor companies I believe will provide you with stable exposure to the situation.
FREE Copy of FAKE by Robert Kiyosaki
My book on the difference between real assets and the fake ones quietly draining the wealth of everyday Americans. Fake money. Fake teachers. Fake assets. The principles inside this book are exactly what The Kiyosaki Letter — and the entire P.I.P. portfolio — are built on. Shipped FREE anywhere in the U.S. Reserved exclusively for Annual Charter Members.
Your investment today is just $149 for the full annual membership — or $49 for a 3-month digital trial.
Choose Your Charter Membership Below
Your 30-Day, 100% Money-Back Guarantee
Try The Kiyosaki Letter for a full 30 days. If it's not for you, we'll refund every penny — and you keep every report.
Your membership includes a 30-day, 100% money-back guarantee. Review every position in the P.I.P. portfolio. Read every Special Report. Track the 42 paydays. Watch the monthly video updates. Read my latest CNXU briefing and the Aesthetics Comps Playbook.
If you decide The Kiyosaki Letter isn't the right fit for the way you invest, simply email support@kiyosakiresearch.com within 30 days of your enrollment and we will refund every penny you paid. No questions asked.
And here's the part most publishers won't tell you: all digital reports are yours to keep, forever, as our gift — even if you cancel. The Tissue Wall Street Can't Print. The Aesthetics Comps Playbook. The Unlikely Hero of the AI Revolution. The Coming Power Wars. The Greenland Opportunity. All of it.
That is how confident I am that once you see the quality of the research inside The Kiyosaki Letter, you'll want to stay.
“The biggest fortunes in this country are not made by people who buy what's already working. They're made by people who can tell the difference between real assets and fake ones — and who get to the real ones first. That is what The Kiyosaki Letter is for.”
Robert Kiyosaki, Editor — The Kiyosaki Letter, Author of FAKE and Rich Dad Poor Dad
The Decision Is Yours
You can close this page and go back to whatever financial information you were getting before. Cable news. The next viral tweet. The next algorithm-driven “stock idea” that lasts six weeks and disappears.
Or you can join the readers who have decided they want one carefully researched real idea per month, a portfolio of real-asset income positions, a growing library of Special Reports, and an editor who has spent forty years teaching people to tell the difference between real assets and fake ones.
Charter Member pricing is reserved for the early enrollees. The full $396-per-year rate is coming — it always does, once a publication finds its audience. Lock in your 62%-off Charter rate today and the price stays yours for as long as you remain a subscriber.
P.S. The full bundle — 12 months of The Kiyosaki Letter, the full P.I.P. Portfolio with 42 paydays per year, all five bonus reports, the Special Reports Library, and a hardcover copy of FAKE — is over $1,600 in total value. Yours today for $149 with the Annual Charter Membership.
P.P.S. The hardcover copy of FAKE is reserved exclusively for Annual Charter Members. If you choose the Quarterly Trial, the book will not be included. And remember: if The Kiyosaki Letter isn't the right fit, just email [SUPPORT EMAIL] within 30 days and we'll refund every penny. You keep every report as our gift. The risk is on us. The opportunity is yours.